AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30882360 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered Escalating Real-Time Adherence (TERA) intervention
Number of subjects: 120
Study 30882360 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 120
Study 30882400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative blood sampling for DNA analysis and questionnaires sent at the third and sixth month after surgery.
Number of subjects: 561
Study 30882905 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 187
Study 30882905 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 187
Study 30882905 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR with delirium
Number of subjects: 187
Study 30882905 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 187
Study 30882905 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 187
Study 30883492 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation
Number of subjects: 0
Study 30883492 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 0
Study 30883492 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning maneuvers
Number of subjects: 0
Study 30883662 — intervention group
Group type: EXPERIMENTAL
Intervention: AdV-tk at doses of 1 × 10^11 and 3 × 10^11 vector particles (vp) injected into the tumor bed followed by 14 days of valacyclovir.
Number of subjects: 8
Study 30883662 — intervention group
Group type: EXPERIMENTAL
Intervention: AdV-tk at dose level 2.
Number of subjects: 8
Study 30883668 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative pain treatment (various analgesic treatments used, including morphine)
Number of subjects: 501
Study 30883668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine consumption
Number of subjects: 501
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried Phenotype
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Trait Scale - short version
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE-FI
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-Items Rockwood Frailty Index
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAIL scale
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gérontopôle Frailty Screening Tool
Number of subjects: 1940
Study 30885132 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call at 6 months
Number of subjects: 1940
Study 30885203 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (n=36)
Number of subjects: 73
Study 30885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients (n=19)
Number of subjects: 73
Study 30885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertensive patients (n=9)
Number of subjects: 73
Study 30885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic hypertensive subjects (n=10)
Number of subjects: 73
Study 30885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (n=9)
Number of subjects: 73
Study 30885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 73
Study 30885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 73
Study 30885203 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 73
Study 30885222 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney patients
Number of subjects: 24
Study 30885222 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 24
Study 30885222 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sodium excretion and plasma sodium
Number of subjects: 24
Study 30885327 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy (carboplatin and etoposide)
Number of subjects: 0
Study 30885327 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 30885354 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical consolidative treatment (RCT)
Number of subjects: 37
Study 30885684 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular Disease assessment
Number of subjects: 0
Study 30885684 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 531
Study 30885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 531
Study 30885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 531
Study 30885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 531
Study 30885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 531
Study 30886935 — intervention group
Group type: EXPERIMENTAL
Intervention: birth environment room
Number of subjects: 680
Study 30886935 — intervention group
Group type: COMPARATOR
Intervention: standard room
Number of subjects: 680
Study 30886950 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Group - technology-enabled counselling intervention including education and counselling by a physical therapist, use of Fitbit and FitViz application, and 4 biweekly follow-up calls from the PT.
Number of subjects: 130
Study 30886950 — intervention group
Group type: COMPARATOR
Intervention: Delayed Group - same program as Immediate Group starting in Week 10.
Number of subjects: 130
Study 30886963 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 124
Study 30886963 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with RA treated with DMARD or healthy controls)
Number of subjects: 124
Study 30886964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg/day for 12 months
Number of subjects: 15
Study 30886974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (high-affinity monoclonal antibody targeting interleukin-17A)
Number of subjects: 0
Study 30886979 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis patients self-reporting PsA
Number of subjects: 0
Study 30886979 — intervention group
Group type: COMPARATOR
Intervention: PsA established by a HCP
Number of subjects: 0
Study 30886990 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pilates exercises, treated twice a week for eight weeks.
Number of subjects: 98
Study 30886990 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercises on treadmills or stationary bikes, treated twice a week for eight weeks.
Number of subjects: 98
Study 30886990 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pilates exercises and Aerobic exercises (both groups), evaluated at baseline, eight weeks, six months, and 12 months after randomization.
Number of subjects: 98
Study 30887180 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg (twice daily) as monotherapy
Number of subjects: 36
Study 30887180 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg (twice daily) as monotherapy
Number of subjects: 36
Study 30887180 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg (twice daily) in combination with paclitaxel (80 mg/m weekly)
Number of subjects: 36
Study 30887180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Olaparib + Paclitaxel)
Number of subjects: 36
Study 30887189 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 141
Study 30887189 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 141
Study 30887189 — intervention group
Group type: COMPARATOR
Intervention: Practitioners at hospitals or mixed practices and specialists
Number of subjects: 141
Study 30887269 — intervention group
Group type: EXPERIMENTAL
Intervention: CFAbd-Score (novel questionnaire)
Number of subjects: 116
Study 30887269 — intervention group
Group type: EXPERIMENTAL
Intervention: CFAbd-Score
Number of subjects: 116
Study 30887820 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial setting (NCT00331773; NCT00004054)
Number of subjects: 7324
Study 30887876 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab administered with a novel patient-controlled injector (One-Press)
Number of subjects: 0
Study 30888024 — intervention group
Group type: EXPERIMENTAL
Intervention: KLRG1-Expressing CD4 T Cells
Number of subjects: 0
Study 30888024 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for tuberculosis
Number of subjects: 0
Study 30888111 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for risk of variceal bleeding comprising of grade 2-3 esophageal varices, red spots, and fibrinogen level <150 mg/dL
Number of subjects: 20
Study 30888111 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation analysis
Number of subjects: 20
Study 30888111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen level, adenosine diphosphate, and thrombin-dependent platelet aggregation
Number of subjects: 20
Study 30888325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile exercise app
Number of subjects: 12
Study 30888398 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian melatonin rhythm in girls with PCOS
Number of subjects: 92
Study 30888398 — intervention group
Group type: COMPARATOR
Intervention: Circadian melatonin rhythm in control subjects
Number of subjects: 92
Study 30888398 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning circadian misalignment
Number of subjects: 92
Study 30888398 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment in girls with PCOS
Number of subjects: 92
Study 30888398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care recommendations
Number of subjects: 92
Study 30888551 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Behavior Inventory (ABI)
Number of subjects: 144
Study 30888551 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI
Number of subjects: 144
Study 30889492 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil at recommended dose (RD) of 35 mg/m² in combination with oxaliplatin
Number of subjects: 24
Study 30889492 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 24
Study 30890162 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely supervised transcranial direct current stimulation (RS-tDCS) administered daily (Monday - Friday) for a total of sixty sessions, 20 minutes of 2.5 mA direct current targeting the cerebellum, paired with cognitive training and physical exercises.
Number of subjects: 1
Study 30890544 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 µg/kg)
Number of subjects: 64
Study 30890548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device, activated monthly before intravenous carboplatin chemotherapy.
Number of subjects: 21
Study 30890548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device.
Number of subjects: 21
Study 30890548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device before carboplatin chemotherapy.
Number of subjects: 21
Study 30890600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) induction followed by 36 months of rituximab maintenance therapy
Number of subjects: 84
Study 30890946 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-AGE dietary intervention
Number of subjects: 0
Study 30890946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian Models
Number of subjects: 0
Study 30891001 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography
Number of subjects: 0
Study 30891607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal delivery of INO-4201
Number of subjects: 0
Study 30891607 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular delivery of INO-4201
Number of subjects: 0
Study 30891607 — intervention group
Group type: COMPARATOR
Intervention: Combination of INO-4201 and INO-4202 with interleukin-12
Number of subjects: 0
Study 30891607 — intervention group
Group type: COMPARATOR
Intervention: Intradermal delivery of INO-4202
Number of subjects: 0
Study 30891607 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular delivery of INO-4202
Number of subjects: 0
Study 30891696 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (cEEG) recording initiated immediately after identification, median cEEG time per patient was 44 hours (interquartile range 21-99 hours).
Number of subjects: 102
Study 30891696 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (cEEG) recording initiated immediately after identification.
Number of subjects: 102
Study 30891962 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Optimization Technique (POT)
Number of subjects: 1191
Study 30891962 — intervention group
Group type: COMPARATOR
Intervention: Non-Proximal Optimization Technique (non-POT)
Number of subjects: 1191
Study 30891964 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB (Left Bundle Branch Block)
Number of subjects: 5157
Study 30891964 — intervention group
Group type: EXPERIMENTAL
Intervention: NICD (Nonspecific Intraventricular Conduction Delay)
Number of subjects: 5157
Study 30891964 — intervention group
Group type: EXPERIMENTAL
Intervention: RBBB (Right Bundle Branch Block)
Number of subjects: 5157
Study 30891964 — intervention group
Group type: COMPARATOR
Intervention: Narrow QRS
Number of subjects: 5157
Study 30891964 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 5157
Study 30891964 — intervention group
Group type: EXPERIMENTAL
Intervention: NICD
Number of subjects: 5157
Study 30891964 — intervention group
Group type: EXPERIMENTAL
Intervention: RBBB
Number of subjects: 5157
Study 30892988 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg per day orally in 28-day cycles plus low-dose cytarabine (LDAC) 20 mg/m²
Number of subjects: 82
Study 30892988 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus LDAC in patients without prior HMA exposure
Number of subjects: 82
Study 30892988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 82
Study 30894288 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 614
Study 30894288 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 614
Study 30895121 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + ADM + PRP
Number of subjects: 12
Study 30895121 — intervention group
Group type: COMPARATOR
Intervention: CAF + ADM
Number of subjects: 12
Study 30895237 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150 μg
Number of subjects: 400
Study 30895237 — intervention group
Group type: COMPARATOR
Intervention: Follitropin beta 300 IU/day
Number of subjects: 400
Study 30895238 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Beckman Coulter Gen II ELISA assay (Premix method)
Number of subjects: 269
Study 30895238 — intervention group
Group type: COMPARATOR
Intervention: Beckman Coulter Gen II ELISA original assay (Gen II original)
Number of subjects: 269
Study 30895236 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy during the follicular phase (on the sixth to eighth day of exogenous stimulation)
Number of subjects: 360
Study 30895236 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy during the follicular phase
Number of subjects: 360
Study 30895243 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. progesterone for luteal phase support
Number of subjects: 0
Study 30895243 — intervention group
Group type: COMPARATOR
Intervention: vaginal progesterone for luteal phase support
Number of subjects: 0
Study 30895244 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL insemination volume
Number of subjects: 269
Study 30895244 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mL insemination volume
Number of subjects: 269
Study 30895467 — intervention group
Group type: EXPERIMENTAL
Intervention: LADA patients with high-titer GADA
Number of subjects: 54
Study 30895467 — intervention group
Group type: COMPARATOR
Intervention: LADA patients with low-titer GADA
Number of subjects: 54
Study 30895945 — intervention group
Group type: EXPERIMENTAL
Intervention: Charge density (CD) mapping
Number of subjects: 0
Study 30895945 — intervention group
Group type: COMPARATOR
Intervention: Voltage measurement
Number of subjects: 0
Study 30895945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of critical points
Number of subjects: 0
Study 30896220 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting
Number of subjects: 202
Study 30896447 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-BCMA cells alone (1-5 x 10^8 cells)
Number of subjects: 25
Study 30896447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^7 cells)
Number of subjects: 25
Study 30896447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^8 cells)
Number of subjects: 25
Study 30896447 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-BCMA infusions with or without lymphodepleting chemotherapy
Number of subjects: 25
Study 30896569 — intervention group
Group type: EXPERIMENTAL
Intervention: Shark mouth pancreaticojejunostomy
Number of subjects: 120
Study 30896610 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI) with identification of 'Purple in Mist' (PIM) in the surface layer, followed by targeted biopsies.
Number of subjects: 63
Study 30896746 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deficiency and estrogen deficiency
Number of subjects: 109
Study 30896746 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deficiency
Number of subjects: 109
Study 30896746 — intervention group
Group type: COMPARATOR
Intervention: Estrogen deficiency but energy replete
Number of subjects: 109
Study 30896779 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Number of subjects: 0
Study 30896779 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 30897531 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen and fibrinogen γ'
Number of subjects: 182
Study 30897531 — intervention group
Group type: COMPARATOR
Intervention: VWF:Ag or ADAMTS13 levels
Number of subjects: 182
Study 30897573 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusions to treat early pregnancy renal anhydramnios (EPRA)
Number of subjects: 0
Study 30897573 — intervention group
Group type: COMPARATOR
Intervention: Untreated EPRA
Number of subjects: 0
Study 30898093 — intervention group
Group type: EXPERIMENTAL
Intervention: TANITA scale
Number of subjects: 38
Study 30898093 — intervention group
Group type: COMPARATOR
Intervention: BIA-BIACORPUS
Number of subjects: 38
Study 30898133 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies identified and defined by the ERIC taxonomy.
Number of subjects: 0
Study 30898133 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly proposed ERIC strategies.
Number of subjects: 0
Study 30898133 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional groupings of ERIC implementation strategies.
Number of subjects: 0
Study 30898164 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 335
Study 30898232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB2) intervention for pulmonary vein isolation (PVI)
Number of subjects: 344
Study 30898249 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruptive calcified nodules
Number of subjects: 1241
Study 30898249 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial calcific sheet
Number of subjects: 1241
Study 30898249 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified protrusion
Number of subjects: 1241
Study 30898607 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 8179
Study 30898607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study 30898821 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Number of subjects: 300
Study 30898821 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Number of subjects: 300
Study 30898849 — intervention group
Group type: EXPERIMENTAL
Intervention: External loop recording (ELR)
Number of subjects: 1412
Study 30898849 — intervention group
Group type: COMPARATOR
Intervention: Continuous ECG
Number of subjects: 1412
Study 30899211 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-BCI-FES device intervention (maximum of 18-30 hours)
Number of subjects: 21
Study 30899211 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 30899278 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-INH(SC) 60 IU/kg twice weekly (n=45)
Number of subjects: 67
Study 30899278 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-INH(IV) 1000 U twice weekly (n=22)
Number of subjects: 67
Study 30899278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30899297 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of spider nevus
Number of subjects: 198
Study 30899297 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of subcutaneous collateral vessel of the chest/abdominal wall
Number of subjects: 198
Study 30899469 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide and bromocriptine
Number of subjects: 1
Study 30899469 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide
Number of subjects: 1
Study 30899835 — intervention group
Group type: EXPERIMENTAL
Intervention: DSJI (disposable-syringe jet injector)
Number of subjects: 128